Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
December 15, 2022 07:48 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
November 17, 2022 06:59 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion CEO comments on strategic focus
November 10, 2022 04:10 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion welcomes Per Norlén as new CEO.
October 05, 2022 08:32 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells
April 25, 2022 08:00 ET
|
Sunshine Biopharma Inc.
MONTREAL, April 25, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology...
Sunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells
April 05, 2022 08:00 ET
|
Sunshine Biopharma Inc.
MONTREAL, April 05, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology...
BioNTech und Regeneron erweitern strategische Zusammenarbeit zur klinischen Entwicklung von FixVac und Libtayo® (Cemiplimab) Kombination gegen nicht-kleinzelliges Lungenkarzinom
March 08, 2022 08:27 ET
|
BioNTech SE
BioNTech und Regeneron planen die gemeinsame Durchführung klinischer Studien zur Untersuchung des FixVac-Kandidaten BNT116 in Kombination mit Libtayo zur Behandlung von fortgeschrittenem...
BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC
March 08, 2022 08:27 ET
|
BioNTech SE
BioNTech and Regeneron plan to jointly conduct clinical trials evaluating FixVac candidate BNT116 in combination with Libtayo for the treatment of advanced non-small cell lung cancer (NSCLC)The...
Peptide Cancer Vaccine Market to Reach USD 10.07 Billion by 2028 - Vast Usage of Peptide Vaccine to Control Tumour Growth Propels the Market Demand – Vantage Market Research
February 15, 2022 03:33 ET
|
Vantage Market Research
WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Peptide Cancer Vaccine Market finds that Peptide Cancer Vaccine aids to provide tumour-specific...
BioNTech erhält FDA-Fast-Track-Status für FixVac-Kandidaten BNT111 bei fortgeschrittenem Melanom
November 19, 2021 06:30 ET
|
BioNTech SE
MAINZ, Deutschland, 19. November 2021 — BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass die US-amerikanische Arzneimittelbehörde (Food and Drug Administration,...